argenx SE GAAP EPS of $8.02 beats by $1.70, revenue of $1.29B misses by $10M
Source: SeekingAlpha
2026-02-26 01:19:02 ET
More on argenx SE
- argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold
- argenx SE Q4 2025 Earnings Preview
- Argenx bid for Vyvgart label expansion undergoes FDA priority review
Read the full article on Seeking Alpha
For further details see:
argenx SE GAAP EPS of $8.02 beats by $1.70, revenue of $1.29B misses by $10M
Argen X SE
NASDAQ: ARGNF
ARGNF Trading
2.56% G/L:
$814.94 Last:
2 Volume:
$814.94 Open:
ARGNF Latest News
March 06, 2026 01:00:00 am
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
February 26, 2026 01:00:00 am
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026 12:30:00 am
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
ARGNF Stock Data
$50,515,067,402
49,738,024
N/A
478
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
